Alto Neuroscience, Inc.
$23.34
The Read: Alto Neuroscience's stock surged about 119% after Q2 2026 earnings due to positive Phase 2a data and a new Phase 2b trial, but then fell about 15% after Q1 2026 earnings as in-line EPS and cash runway updates failed to boost investor confidence.
Price
Overlays
Panel
ANRO
Hover to view data
No Data